BioSpace News Archive

Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents announced today that its preliminary unaudited revenue for the fiscal first quarter ended March 31, 2020 will be near the top end of previously disclosed guidance range issued on Februar

Laurent Pharmaceuticals to initiate world-first testing of LAU-7b in COVID-19 patients

Abbott (NYSE: ABT) today announced that its TriClip™ Transcatheter Tricuspid Valve Repair System has received CE Mark and is now approved for use in Europe and other countries that recognize CE Mark as a non-surgical treatment for people with a leaky tricuspid valve, a condition known as tricuspid regurgitation (TR).

Excelra, a leading global data and analytics company, today announced the release of the COVID-19 Drug Repurposing Database (https://www.excelra.com/covid-19-drug-repurposing-database/).

Agion® Antimicrobial (AM) by Sciessent, a U.S.-based provider of antimicrobial (AM) solutions based on naturally occurring elements, is incorporated into FDA cleared N95 respirator masks, the type most in-demand in the fight against the COVID-19 pandemic.

Paradigm, the industry leader in solving catastrophic and complex health care challenges and improving lives, today announced a new COVID-19 solution designed to assist injured workers requiring medical care and support for recovery from the Coronavirus disease 2019 (COVID-19).

MedPresence® Telemedicine Solution Contributes to Physician Collaboration while Limiting Exposure for Staff and Patients

EicOsis LLC, a pharmaceutical startup developing a new class of oral non-narcotic analgesics based on inhibition of the soluble Epoxide Hydrolase (sEH) enzyme, announced today that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to its lead drug candidate, EC5026, for the treatment of neuropathic pain.

Cipla Limited (BSE: 500087) (NSE: CIPLA EQ); (and hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation, from the United States Food and Drug Administration (US FDA). Cipla’s Albuterol S

Horizon Therapeutics plc (NASDAQ:HZNP) today announced it has been selected as one of the 2020 Best Workplaces in Health Care and Biopharma by Fortune and Great Place to Work®.